New regimens based on 2 or more novel agents are sought to shorten or to simplify
treatment of tuberculosis (TB), including drug-resistant forms. Prior studies showed that the …

Novel regimens combining bedaquiline and pretomanid with either linezolid (BPaL regimen)
or moxifloxacin and pyrazinamide (BPaMZ regimen) shorten the treatment duration needed …

New regimens based on two or more novel agents are sought to shorten or simplify
treatment of tuberculosis (TB). Pretomanid (PMD) is a nitroimidazole in phase 3 trials that …

The combination of bedaquiline, pretomanid, and linezolid (BPaL) has become a preferred
regimen for treating multidrug-and extensively drug-resistant tuberculosis (TB). However …

Rationale: New regimens to shorten tuberculosis treatment and manage patients with drug-
resistant tuberculosis who are infected with HIV are urgently needed. Experimental and …

ABSTRACT A regimen comprised of bedaquiline (BDQ, or B), pretomanid, and linezolid
(BPaL) is the first oral 6-month regimen approved by the US Food and Drug Administration …

Novel oral regimens composed of new drugs with potent activity against Mycobacterium
tuberculosis and no cross-resistance with existing agents are needed to shorten and simplify …

New regimens based on two or more novel agents are sought in order to shorten or simplify
the treatment of both drug-susceptible and drug-resistant forms of tuberculosis. PA-824 is a …

ABSTRACT TBI-166, derived from riminophenazine analogues, shows more potent anti-TB
activity than clofazimine and is being assessed against tuberculosis (TB) in a phase IIa …

Background New anti-tuberculosis (TB) regimens are needed to treat drug sensitive (DS)
and multi-drug resistant (MDR) TB. NC-005 is an ongoing Phase 2b open-label, partly …